Drug · CHEMBL998
LORATADINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. LORATADINE. Drugs and targets, record CHEMBL998. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL998
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
Alavert, Children's claritin, Claritin, Claritin hives relief, Claritin hives relief reditab, Claritin reditabs, Clarityn, Clarityn rapide, Clarityne, Hay-rite, Loratadine component of claritin-d, Loratadine redidose, Roletra
- ChEMBL
- Open Targets' highest stage
- Approval, for 7 of its 15 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| HRH1 | Histamine H1 receptor | Histamine H1 receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/3269 |
Source ChEMBL
Diseases15
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 15Source Open Targets
See all 15 diseasesTrials63
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00972738 | Montelukast in Seasonal Allergic Rhinitis - Spring 2001 Study (0476-235) | Phase 3 | 1,214 | 2010-06-16 | loratadine | Its name | ClinicalTrials.gov |
| NCT00963469 | Montelukast in Seasonal Allergic Rhinitis: Fall 2001 Study (0476-240) | Phase 3 | 1,079 | 2010-06-09 | loratadine | Its name | ClinicalTrials.gov |
| NCT00963599 | Montelukast in Seasonal Allergic Rhinitis - Fall 1999 Study (0476A-117) | Phase 3 | 907 | 2010-06-16 | loratadine | Its name | ClinicalTrials.gov |
| NCT03855228 | Safety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Loratadine Versus Placebo in Participants With Seasonal Allergic Rhinitis (C94-145) | Phase 3 | 704 | 2019-07-26 | loratadine | Its name | ClinicalTrials.gov |
| NCT01712009 | NOLAN: Naproxen or Loratadine and Neulasta | Phase 2 | 600 | 2016-03-09 | loratadine | Its name | ClinicalTrials.gov |
| NCT01413958 | Effects of Phenylephrine Extended-Release Tablets on Allergy-Related Nasal Congestion (P08498 AM1) | Phase 3 | 575 | 2013-01-29 | loratadine | Its name | ClinicalTrials.gov |
| NCT04162795 | A Study to Evaluate Cooling Sensation of an Allergy Product in Adults With a History of Allergies | Phase 4 | 468 | 2021-02-04 | loratadine | Its name | ClinicalTrials.gov |
| NCT01451996 | The Efficacy of Claritin in Healthy Subjects | Phase 4 | 340 | 2018-03-13 | loratadine | Its name | ClinicalTrials.gov |
| NCT00730912 | Post Approval Pharmacokinetic Study of Loratadine in Japanese Pediatric and Adult Patients (Study P05539) | Phase 4 | 261 | 2010-07-05 | loratadine | Its name | ClinicalTrials.gov |
| NCT01469234 | A Study of Onset of Action of Loratadine and Fexofenadine in Participants With Seasonal Allergic Rhinitis (P08712) | Phase 4 | 255 | 2013-03-22 | loratadine | Its name | ClinicalTrials.gov |
1 to 10 of 63
See all 63 trialsComparisons in its trials7
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Phenylephrine vs Placebo: serious adverse events | 0 of 288 | 0 of 287 | 575 | NCT01413958 | Trial comparisons |
| TAA-AQ vs Placebo: serious adverse events | 0 of 69 | 1 of 71 | 140 | NCT01154153 | Trial comparisons |
| Montelukast 10 mg/Loratadine 10 mg vs Placebo: Number of Participants Discontinuing Study Treatment Due to AEs | 1 of 47 | 0 of 22 | 69 | NCT01673620 | Trial comparisons |
| Montelukast 10 mg/Loratadine 10 mg vs Placebo: Number of Participants Experiencing at Least One Adverse Event (AE) | 6 of 47 | 2 of 22 | 69 | NCT01673620 | Trial comparisons |
| Montelukast 10 mg/Loratadine 10 mg vs Placebo: serious adverse events | 0 of 47 | 0 of 22 | 69 | NCT01673620 | Trial comparisons |
| Loratadine First vs Placebo First: deaths from any cause | 0 of 2 | 0 of 1 | 3 | NCT03883386 | Trial comparisons |
| Loratadine First vs Placebo First: serious adverse events | 0 of 2 | 0 of 1 | 3 | NCT03883386 | Trial comparisons |
Papers from its trials18
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials1
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome |
|---|---|---|
| Stroop Color-Word Test | 1 | 0 |
Source ConductCognition
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL998
GET https://conductscience.org/api/drugs/v1/CHEMBL998/trials?page=2